Montauk Renewables Provides 4Q Production Guidance, Says Weather Hurt 3Q Output — Commodity Comment
By Adam L. Cataldo
Montauk Renewables, an energy company specializing in the management, recovery and conversion of biogas into renewable natural gas, updated their production forecast for the fourth quarter.
The company also said weather anomalies such as lower-than-average rainfall and higher-than-average temperatures contributed to the reduction in D3 RIN generation in the third quarter.
On the outlook for RNG production volumes in 4Q:
Volumes are expected to range between 5.7 million and 5.8 million MMBtu.
On the outlook for renewable electricity production volumes in 4Q:
Volumes are expected to range between 190 and 195 thousand MWh.
Write to Adam Cataldo at adam.cataldo@wsj.com
(END) Dow Jones Newswires
November 09, 2023 19:57 ET (00:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track